ClinicalTrials.gov
public full text
Public Domain
IC14 Antibodies to Treat Individuals With Acute Lung Injury
This is a phase II, randomized, double-blind, placebo-controlled, safety and efficacy study of a recombinant chimeric monoclonal antibody against CD14 (IC14) in hospitalized patients with acute lung injury (ALI).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pilot Study on Cytokine Filtration in COVID-19 ARDS#917394
- IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy#343834
- Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia#968260
- Trained immunity in lung injury and repair.#152258
- Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection#866497
Record · ID 1093693
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive